Uhlmann Group Spins Off visiotec GmbH
New company will focus on inspection, monitoring, and control systems for automated pharmaceutical manufacturing processes.
An independent subsidiary of Uhlmann Germany, visiotec GmbH, was created on April 1, 2013 to focus on inspection, monitoring, and control systems for automated pharmaceutical manufacturing processes, the company announced in a press release.
The spin-off addresses the pharmaceutical industry’s demand for a more holistic approach beyond the traditional borders of manufacturing and packaging, said the company. Visiotec will provide solutions for product quality and safety using inline monitoring, based on its expertise in process analytical technologies, such as high-speed, near-infrared analysis and advanced mass-verification technology.
Visiotec GmbH will operate globally from offices in Germany, Switzerland, and the United States. The printing, inspection, and track-and-trace products formerly offered by Uhlmann VisioTec GmbH for packaging applications will be handled by the Uhlmann Group’s dedicated Uhlmann Customer Services division.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
